Sociodemographics and scores on measures of AD pathology (PET Aβ and tau) and symptomatology (cognitive performance and depressive symptoms or depressive disorder), were then compared between the group of participants who screened positive for OSA versus those who screened negative on the WatchPAT home sleep study. The gene discussed is MAPT; the disease is Alzheimer disease.